Objective and Rationale
• To compare major outcomes for pts remaining on blinded monotherapy.
• Aim: to remove effects of step-up drugs that may have differed in effectiveness depending on Step 1 class. • Main limitation: departure from intent-totreat introduces possible confounding.
ALLHAT
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart failure, increased in the assigned (intent-to-treat)
Step 1 amlodipine and doxazosin treatment groups compared to the chlorthalidone group, is similarly increased in these treatment groups in this
Step 1 monotherapy cohort.

Conclusions (2)
The previously reported higher rates for stroke and CCVD, including heart failure, in the lisinopril group compared to the chlorthalidone group, do not reach significance in this monotherapy cohort.
-The restricted cohort lessens the sample size. -BP differences are greatly diminished with this restricted cohort. -Participants with early CVD events are not included.
ALLHAT
Conclusions (3)
Unknown confounding factors may further influence results, and thus caution in interpretation is warranted.
ALLHAT
Alternate Slides
Heart Failure in ALLHAT ALLHAT † Time-dependent variables: SBP, DBP, on/off treatment, and serum potassium, creatinine, and cholesterol; also adjusted for baseline variables * P < 0.05
